Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205641 | 0.86 | AAK1 (0.38) | TSHRMEN1KMT2AAAK1NPSR1 | |
| SCHEMBL26205638 | 0.85 | AAK1 (0.39) | TSHRMEN1KMT2AAAK1LMNA | |
| SCHEMBL26205634 | 0.80 | KMT2A (0.39) | MEN1KMT2A | |
| SCHEMBL26205631 | 0.78 | MAPT (0.44) | TSHRMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL22526231 | 0.78 | AAK1 (0.61) | AAK1PTGER1 | |
| SCHEMBL26206371 | 0.77 | S1PR1 (0.39) | ALOX5 | |
| SCHEMBL26205645 | 0.77 | MRGPRX4 (0.43) | MEN1KMT2APTGER1ALDH1A1KDM4E | |
| SCHEMBL26205633 | 0.76 | HSD17B10 (0.48) | KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL27015309 | 0.76 | PTGER1 (0.34) | TSHRMEN1KMT2APTGER1ALDH1A1 | |
| SCHEMBL22714369 | 0.76 | TSHR (0.43) | TSHRMEN1KMT2AAAK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | TSHR 1768/4885MEN1 3280/4885KMT2A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.